Edgewise Therapeutics appoints Michael Nofi as CFO, succeeding retiring CFO Carruthers

Edgewise Therapeutics, Inc.

Michael Nofi appointed CFO effective Nov 10, 2025; replaces R. Michael Carruthers who retired.
Nofi's annual base salary: $465,000, target cash bonus 40% of salary, plus stock option for 262,500 shares and 43,750 RSUs.
Carruthers to remain employee until Jan 31, 2026, then consultant through Oct 31, 2026, with continued equity vesting.
Nofi previously Chief Accounting Officer at SpringWorks Therapeutics; brings 30+ years life sciences finance experience.
No disagreement between Carruthers and company; transition supports Edgewise's late-stage clinical and commercialization prep.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.